Peptides for biopharmaceutical applications
MetadataShow full item record
© 2018 Elsevier Ltd. All rights reserved. In the pharmaceutical industry, organic-based small molecules have been the most widely used therapeutics, but peptides are increasingly becoming an important class of therapeutic agent for biopharmaceutical applications. This trend is enhanced by research advances that have provided cutting-edge techniques and strategies to overcome challenges often encountered with the use of peptides. By their nature, peptide pharmaceutics are plagued with high cost of production, poor solubility, and difficulty in administration. However, the use of techniques such as peptide engineering, peptide conjugation, and formulation strategies to improve parenteral delivery are paving the way for an increased use of peptides as biologics. With these drivers, peptides are anticipated to occupy an increased share of use in the treatment of health conditions, as well as in performance on the therapeutics market. This chapter gives an overview of the drivers, restrains, and advances in the application of peptides as biopharmaceutical agents.
Showing items related by title, author, creator and subject.
Namjoshi, Sarika M (2009)Recent developments in genetic engineering and biotechnology have resulted in anincrease in availability of therapeutic peptides and small anti-cytokines. Oraladministration is inappropriate as these molecules are unstable ...
Lazoura, E.; Lodding, J.; Farrugia, W.; Day, S.; Ramsland, Paul; Apostolopoulos, V. (2009)The major histocompatibility complex (MHC) on the surface of antigen presenting cells functions to display peptides to the T cell receptor (TCR). Recognition of peptide-MHC by T cells initiates a cascade of signals, which ...
Altered peptide ligands of myelin basic protein (MBP87-99) conjugated to reduced mannan modulate immune responses in miceKatsara, M.; Yuriev, E.; Ramsland, Paul; Tselios, T.; Deraos, G.; Lourbopoulos, A.; Grigoriadis, N.; Matsoukas, J.; Apostolopoulos, V. (2009)Mutations of peptides to generate altered peptide ligands, capable of switching immune responses from T helper 1 (Th1) to T helper 2 (Th2), are promising candidates for the immunotherapy of autoimmune diseases such as ...